QUOIN PHARMACEUTICALS LT-ADR
QNRXNASDAQ🏆 #3793 by market capUS Equity
$638.34▼ $12.58 (−1.97%)
Simulated price1h—
24h▼ 2.0%
7d▲ 14180.5%
14d▲ 14919.8%
30d▲ 14814.5%
1y▲ 8729.0%
🏦Market Cap
$11M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
51
Weak
Trading Snapshot
- Day Range
- $629.71 – $641.84
- 52-Week Range
- $3.25 – $41.80
- Volume
- $2.94B
- Avg Volume
- $3.56B
- Shares Outstanding
- 70.3M
- Next Earnings
- Sep 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $812,366
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-16.49
- Dividend Yield
- —
Why Investors Own QNRX
- ✓High-growth profile — revenue up +6.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 59% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$3M▲ +5.4% YoY
Gross Margin (TTM)
59.3%▲ +1.9% YoY
Operating Income (TTM)
$396,455▲ +5.4% YoY
Free Cash Flow (TTM)
$159,183▲ +5.4% YoY
About QUOIN PHARMACEUTICALS LT-ADR
A company profile for QUOIN PHARMACEUTICALS LT-ADR isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
51/100
Analyst Price Target
ⓘAverage Target
$699.18
▲ +9.5% Upside
High Target$823.65
Low Target$613.30
Based on 14 analysts
Latest News & Updates
🚀
Barron’s·2h ago
QUOIN PHARMACEUTICALS LT-ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift QNRX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
QUOIN PHARMACEUTICALS LT-ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.